Conference Coverage

Long-acting basal insulin controls HbA1c as well as glargine

Publish date: September 16, 2015

 

AT EASD 2015

References

Eli Lilly & Co. funded the study. Dr. Garg has received research funding from the company.

msullivan@frontlinemedcom.com

Pages

Recommended Reading

HbA1c aids prediction of atherosclerotic CVD
Type 2 Diabetes ICYMI
High-calorie American diet causes insulin resistance within days
Type 2 Diabetes ICYMI
So much sugar in long-term care
Type 2 Diabetes ICYMI
FDA issues revised warning for adverse effects associated with canagliflozin
Type 2 Diabetes ICYMI
A Treatment Protocol for Patients With Diabetic Peripheral Neuropathy
Type 2 Diabetes ICYMI
High-calorie American Diet Causes Insulin Resistance Within Days
Type 2 Diabetes ICYMI
ESC: Further data indicate no excess heart failure risk with lixisenatide or sitagliptin
Type 2 Diabetes ICYMI
EASD: High HbA1c linked to elevated dementia risk in patients with 2DM
Type 2 Diabetes ICYMI
EASD: Intranasal glucagon reverses hypoglycemia in children and adolescents
Type 2 Diabetes ICYMI
EASD: High A1C Linked to Elevated Dementia Risk in Patients With T2DM
Type 2 Diabetes ICYMI